Drug profile · INN
talquetamab
TALVEY
talquetamab (TALVEY) is a t cell surface glycoprotein cd3 binding agent.
EMA: approved Antineoplastic and immunomodulating agents (L01) L01FX29
Patents linked 0
Pipeline programs 2
News articles 1
Drug details — talquetamab
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 0
- Programs
- 2
- Data quality
- 0.83
Quick answer
talquetamab (TALVEY) is a t cell surface glycoprotein cd3 binding agent.
Key facts
INN talquetamab
Brand TALVEY
Mechanism T cell surface glycoprotein CD3 binding agent
Target G-protein coupled receptor family C group 5 member D
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01FX29
Mechanism of action
T cell surface glycoprotein CD3 binding agent
Primary target: G-protein coupled receptor family C group 5 member D
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is talquetamab?
talquetamab (TALVEY) is a t cell surface glycoprotein cd3 binding agent.
What is the brand name for talquetamab?
TALVEY is a marketed brand name for talquetamab. Check FDA Drugs@FDA for the current US label holder and prescribing information.